SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$7.28
Market Cap
$780.60M
52W High
$11.45
52W Low
$3.79
ADV30
1,123,827
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -57,384,000 | -54,799,000 | 420,580,000 | 159,394,000 | 46,505,000 |
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
| Sep 2025 | 0 | — | -48,058,000 | -45,776,000 | 273,914,000 | 61,364,000 | 55,966,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-186,844,000
Investing CF
$-87,090,000
Financing CF
$293,817,000
CapEx
$-965,000
Dividends Paid
—
Buybacks
$-13,644,000
EPS Diluted TTM
$-1.80
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,069,311,000
Inventory
—
Receivables
—
ST Investments
$218,284,000
EBIT TTM
$-208,997,000
Pretax Income TTM
$-207,099,000
Interest Exp TTM
$128,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | 180,010,000 | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | 137,246,000 | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | 126,481,000 | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | 211,666,000 | -97,977,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.75
Max Pain — expiry 2026-12-18
max pain strike: $7.00 · spot: $7.28 · call oi: 1,230 · put oi: 22
Expected Move to 2026-12-18:
±$3.35
(46.02%) —
implied range
$3.93 –
$10.63
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DBVTF | DBV Technologies S.A. | $790.01M | $2.51 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $804.36M | $14.56 | — |
| DBVT | DBV Technologies S.A. | $731.56M | $11.64 | — |
| CADL | Candel Therapeutics, Inc. | $856.24M | $11.19 | — |
| SANA | Sana Biotechnology, Inc. | $877.13M | $2.93 | — |
News headlines (Yahoo Finance, 1h cache)
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
2026-07-02 03:28 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:05 · Yahoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 20:08 · Yahoo
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
2026-05-07 12:00 · Yahoo
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
2026-04-30 12:00 · Yahoo
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
2026-04-28 12:00 · Yahoo
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 20:08 · Yahoo
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
2026-06-18 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.